ORANGE COUNTY, California, Nov. 1, 2017 — MediPines announced today that it has acquired medical technology designed to reduce respiratory complications in post-surgical patients by preventing oxygen desaturations (i.e. low oxygen levels). The technology called “Oxistimulator” was originally invented by clinical practitioners at the Department of Anesthesiology at Mayo Clinic and exclusively licensed to California-based medical device company, MediPines Corporation.
After surgery, many patients are at risk of oxygen-related complications due to pre-existing conditions (e.g. obstructive sleep apnea) that can be exacerbated by the pain medications they are receiving. The Oxistimulator is a new, non-invasive technology that aims to prevent post-operative desaturations and complications by providing timely, peripheral “tactile stimulation” whenever clinically-defined desaturations are detected.
“We believe Oxistimulator has tremendous potential to improve care for many at-risk patients, and are very excited to bring this meaningful technology to realization,” says Steve Lee, CEO of MediPines.
“These pain medications can cause severe side effects such as low oxygen levels or desaturations and cessation of respiration. We want to treat the pain accurately and to the best of our ability, but the pain medications can have side effects with sometimes devastating consequences,” says Bradly Narr, M.D., chair of the Surgical and Procedural Committee and a former chair of the Department of Anesthesiology at Mayo Clinic’s Rochester campus.
Mayo Clinic is currently conducting a clinical study to assess whether the device significantly reduces desaturations for at-risk patients and to demonstrate product safety with minimal side effects.
The new technology is not yet approved for commercial use. Mayo Clinic will use any revenue it receives from the financial performance of the technology referenced in this news release to support its not-for-profit mission in patient care, education and research.